Roche culls development of two Huntington’s disease programmes
Roche has stopped development of two of its Huntington’s disease candidates after one failed to show benefit in…
Roche and Zealand’s Phase II obesity trial divides analyst opinion
Roche and Zealand Pharma’s co-developed amylin analogue, petrelintide, has met its primary endpoint in a Phase II trial,…
Roche Phase II weight-loss drug trims 10.7% vs placebo
Roche (OTCQX: RHHBY) reported positive Phase II ZUPREME-1 topline results for petrelintide, an…
Roche Advances Obesity Pipeline as Petrelintide Meets Phase II Goal
Roche RHHBY has announced that the mid-stage study ZUPREME-1, evaluating the investigational candidate petrelintide for the treatment of…
Roche obesity drug CT-388 cuts weight 22.5% in Phase II
Roche (OTCQX: RHHBY) reported positive Phase II topline results for CT-388, a once-weekly…